This is a rare type of bone cancer that starts in the notochord, which is a structure that develops into the spine during pregnancy. It can occur anywhere along the spine, from the base of the skull down to the tailbone. It's called chordoma because it originates from the remnants of the notochord.
Every report comes from a Lived member, sent anonymously.
Have you tried Radiation Therapy for Chordoma?
Chordoma is a rare, slow-growing cancer that forms in the bones of the spine and the base of the skull. It most often starts near the tailbone (the sacrum) or where the spine meets the skull (an area called the clivus), though it can occur anywhere along the spine. About one in a million people are diagnosed each year, most often in their 50s and 60s, and children account for about 5% of cases. A rarer form seen mostly in children can grow faster. Chordoma develops from leftover cells of the notochord, a structure that guides the formation of the spine before birth and normally disappears. Because the tumor grows slowly, people may notice nothing for years. What makes chordoma serious is less its speed than its location: it grows next to the spinal cord, nerves, brain and major blood vessels, and it has a strong tendency to come back after treatment.
Researchers do not yet know what starts most chordomas. Many tumors show changes involving brachyury, a protein made by the TBXT gene that is active in notochord cells, and this is a major focus of research into new treatments. Chordoma rarely runs in families. A few families have several affected members, but for most people the risk of passing chordoma on to their children is low.
Symptoms depend on where the tumor sits. A chordoma at the skull base can cause headaches or double vision. One near the tailbone can cause pain that may spread down the legs and trouble controlling the bladder or bowels. Because these symptoms build slowly and are common to many other problems, it can take a long time to reach the diagnosis. An MRI scan shows the size of the tumor and exactly what it is pressing on, and a CT scan helps show the bone and whether the tumor has spread. A biopsy, in which a small sample is taken with a needle, confirms the diagnosis when a pathologist sees cells that resemble notochord cells under the microscope. Tumor cells can occasionally take hold along a biopsy or surgical path, which is one reason experts advise that the biopsy and treatment be planned by a specialized team from the start.
The standard approach is to remove as much of the tumor as can be taken out safely, followed by high-dose, precisely targeted radiation therapy, such as proton therapy. When surgery is not possible, radiation can be used on its own. International experts recommend that treatment take place at an experienced center where surgeons, radiation oncologists and other specialists plan care together, because the first treatment offers the best chance of long-term control. The main trade-off is that chordoma sits close to structures that control movement, sensation, vision, swallowing, and bladder and bowel function. Removing the whole tumor with a margin of healthy tissue lowers the chance of it coming back, but it can mean sacrificing nerves or other tissue, so the plan weighs tumor control against the function a person wants to keep. Standard chemotherapy generally does not work against chordoma. No medicine is approved by the US Food and Drug Administration (FDA) specifically for it, so doctors use medicines approved for other cancers (off-label use) for advanced or recurrent disease. The one used most often is imatinib (Gleevec), a targeted cancer pill. In a recent European series of targeted drugs, mostly imatinib, tumors shrank measurably in about 6 of every 100 treatment courses, and on average the tumor started growing again after about six months. Clinical trials, including immunotherapy approaches that target brachyury, are an important option to discuss.
Chordoma is a long-term condition even after successful treatment. More than half of people whose tumor was fully removed see it return in the same area, and many recurrences happen 5 or 10 years later. Regular MRI scans continue for many years so that any return is caught early, when more options remain. Over the course of the illness, chordoma also spreads to other parts of the body in roughly 40% to 60% of people. Outlook varies widely. It depends on where the tumor is, whether it has spread and how much could be removed at the first operation. Survival estimates come from small numbers of patients and older treatments, but on average people live around 10 years after diagnosis, and some are cured. A tumor that comes back is much harder to control, though some people still achieve long periods of stable disease and good quality of life. Daily life after treatment is shaped by the tumor's location. Some people live with lasting nerve-related effects such as changes in walking or in bladder and bowel control after sacral surgery, or vision or swallowing changes after skull base treatment. Rehabilitation, pain management and support services are part of care, and patient organizations can help connect people with specialists and others living with this rare cancer.
See a clinician if back, tailbone or neck pain persists without explanation, or if you develop ongoing headaches, double vision or changes in swallowing or speech. Mention any numbness, weakness or bladder or bowel changes that have come on gradually. If you have been treated for chordoma, contact your care team promptly about new or worsening pain, weakness, numbness, bladder or bowel changes, or new vision or swallowing problems, since these can signal that the tumor has returned. Keep every scheduled follow-up scan, even after many years without problems. Whether or not you have been diagnosed, sudden loss of bladder or bowel control, new numbness between the legs or around the buttocks, or leg weakness that is getting worse quickly needs emergency care right away. These can mean the spinal cord or nerves are being squeezed, and fast treatment can help preserve function.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Chordoma is like, what's helped you, or ask the community a question.